JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: Canagliflozin (also known as TA 7284; JNJ 24831754ZAE; JNJ 28431754AAA; JNJ 28431754) is a highly potent and selective SGLT2 inhibitor for hSGLT2 with IC50 of 2.2 nM in a cell-free assay, it exhibits 413-fold selectivity over hSGLT1. Canagliflozin is a FDA approved drug for the treatment of type 2 diabetes. Canagliflozin is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine. Canagliflozin was approved by the FDA on March 29, 2013, and became the first SGLT2 inhibitor approved in the USA.
References: PLoS One. 2012; 7(2):e30555; J Med Chem. 2010 Sep 9; 53(17):6355-60
Related CAS#: 928672-86-0 (hemihydrate); 842133-18-0 (free)
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!